17 citations,
January 1995 in “The American Journal of Medicine”
The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.
The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgenreceptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgenreceptors in hair follicles, potentially offering fewer side effects.
RU58841 may cause heart-related side effects like palpitations and chest pain, though evidence is mostly anecdotal. Users report mixed experiences, with some stopping due to side effects and others using it without issues, but concerns about its safety and sourcing remain.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
RU58841 is debated for hair loss treatment, with concerns about safety and effectiveness. Some users prefer premixed solutions despite higher costs, while others report issues with DIY methods and potential health risks.